Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC

Video

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program at Mount Sinai School of Medicine and professor at the University of Barcelona, discusses the results from the phase III REACH-2 study of ramucirumab (Cyramza) as a second-line treatment of patients with advanced hepatocellular carcinoma (HCC).

Data showed that ramucirumab was significantly better than placebo in terms of overall survival at 8.2 months versus 7 months, respectively.

Llovet also discussed the results of a meta-analysis, which evaluated patients with alpha-fetoprotein (AFP) levels greater than 400 from both the REACH and REACH-2 trials. There were slightly better outcomes in this patient population where the 5-month median survival improved to 8 months, Llovet says. This is a key takeaway from this trial, he concluded.

REACH-2 is a follow-up to the phase III REACH trial. In June 2014, Eli Lilly Oncology, the developer of ramucirumab, reported that in the REACH study, second-line treatment with ramucirumab did not improve OS compared with placebo in the full population of patients with advanced HCC.

View more from the 2019 Gastrointestinal Cancers Symposium

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center